Observational studyGut and liver2026

Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease.

Yu Kyung Jun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.